Browsing Tag
FDA approval
131 posts
Celltrion USA launches ZYMFENTRA for ulcerative colitis and Crohn’s disease
In a significant advancement for patients with digestive disorders, Celltrion USA has announced the availability of ZYMFENTRA (infliximab-dyyb),…
FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally…
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction in adults with obesity
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk’s Wegovy, a…
Bristol Myers Squibb announces Opdivo FDA approval for urothelial carcinoma
In a significant stride toward enhancing bladder cancer treatment, Bristol Myers Squibb (NYSE: BMY) announced the U.S. Food…
IM Cannabis and Kadimastem announce reverse merger deal
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), known for its significant strides in the medical cannabis sector, has…
Can Glenmark Pharmaceuticals’ FDA approval for Enstilar Foam generic boost its U.S. dermatology footprint?
Glenmark Pharmaceuticals secures FDA approval for its generic version of Enstilar Foam, aiming to expand its U.S. dermatology market presence.
FDA approves G1 Therapeutics’ Cosela for reducing chemotherapy-induced bone marrow suppression
G1 Therapeutics has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of…
Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj),…
Biocon launches generic Tacrolimus in U.S.: A gamechanger in transplant care
Find out how Biocon’s launch of generic Tacrolimus in the U.S. marks a strategic leap in affordable transplant care and global generic market expansion.
AstraZeneca wins FDA approval for Tagrisso in adjuvant treatment of early-stage NSCLC patients with EGFR mutations
Find out how AstraZeneca’s expanded FDA approval for Tagrisso is transforming early-stage lung cancer treatment standards.